【ScinoPharm】Important Resolutions of the 115 Annual General Shareholders' Meeting
Key facts
- 【ScinoPharm】Important Resolutions of the 115 Annual General Shareholders' Meeting
- ScinoPharm held its Annual General Shareholders' Meeting on May 27, 115, approving a cash dividend of 0.29 TWD per share for the 114 fiscal year. The meeting also passed amendments to the Articles of Incorporation, asset disposal procedures, and the lifting of non-compete restrictions for directors.
- Source: PR Times
- Date: May 27, 2026
Direct answer
ScinoPharm held its Annual General Shareholders' Meeting on May 27, 115, approving a cash dividend of 0.29 TWD per share for the 114 fiscal year. The meeting also passed amendments to the Articles of Incorporation, asset disposal procedures, and the lifting of non-compete restrictions for directors.
- Citation
- 【ScinoPharm】Important Resolutions of the 115 Annual General Shareholders' Meeting (May 27, 2026), PR Times
- Source
- PR Times
- Date
- May 27, 2026
ScinoPharm held its Annual General Shareholders' Meeting on May 27, 115, approving a cash dividend of 0.29 TWD per share for the 114 fiscal year. The meeting also passed amendments to the Articles of Incorporation, asset disposal procedures, and the lifting of non-compete restrictions for directors.
📋 Article Processing Timeline
- 📰 Published: May 27, 2026 at 09:00
- 🔍 Collected: May 28, 2026 at 08:00 (23h 0m after Published)
- 🤖 AI Analyzed: May 31, 2026 at 18:51 (82h 51m after Collected)
FAQ
When will the dividends be paid?
The specific payment date will be announced separately by the company.
What does lifting non-compete restrictions mean?
It allows directors to hold positions in other companies, facilitating broader industry collaboration.
What are the key facts in this article?
ScinoPharm held its Annual General Shareholders' Meeting on May 27, 115, approving a cash dividend of 0.29 TWD per share for the 114 fiscal year. The meeting also passed amendments to the Articles of Incorporation, asset disposal procedures, and the lifting of non-compete restrictions for directors.